Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.

An excellent addition to current resources in psychopharmacology for graduate and postgraduate trainees in psychiatry, neurology, medicine, pharmacy and pharmacology. A comprehensive series of relevant questions and an extensive bibliography that will be both a useful test of trainees’ progress and also a useful aide memoire and primer. Consists of 2600 questions in the form of ‘True/False Individual Statements, Extended Matching Items and Best of Five’ formats, organised in 52 papers in two volumes

Translating bench-based research into effective bedside practice, this source provides a clear understanding of the neurobiology and neurogenetics of psychiatric disorders, the genes responsible for specific psychiatric disorders, and the implications of genetic roots and underlying biology on the development of new diagnostic approaches and treatment therapies.

The rapidly evolving field of Pharmacogenetics aims at identifying the genetic factors implicated in the inter-individual variation of drug response. These factors could enable patient sub-classification based on their treatment needs thus expediting drug development and promoting personalized, safer and more effective treatments. This book presents Pharmacogenetic examples from a broad spectrum of different drugs, for different diseases, which are representative of different stages of evaluation or application. It has been designed so as to serve both the unfamiliar reader through explanations of basic Pharmacogenetic concepts, the clinician with presentation of the latest developments and international guidelines, and the research scientist with examples of Pharmacogenetic applications, discussions on the limitations and an outlook on the new scientific trends in this field.

Quick and comprehensive information on psychotropic drugs for children and adolescents. Accurate and up-to-date Specific to children and adolescents Charts and tables help decision-making Icons and full color More about this book The Clinical Handbook of Psychotropic Drugs for Children and Adolescents is a unique resource to help you make the right choices about psychotropic medications for younger patients. The fifth edition of this widely acclaimed reference has been fully updated and expanded. Updated information on psychiatric disorders in children and adolescents Unique comparison charts (dosages, side effects, pharmacokinetics, interactions...) that allow you to see at a glance which medication is the most suitable for each patient Instantly recognizable icons in full color throughout, allowing you to quickly find all the information you seek: – General information on medications, availability, and indications – Drug action, dosing, pharmacokinetics, and related areas – Warnings and precautions – Patient-related information, such as lab monitoring recommendations, nursing implications, and patient advice Clearly written patient and caregiver information sheets as printable pdf files This book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs. New in this edition: New chapters on Prescribing Safely and Ethically to Children and Adolescents, Pharmacogenetic Information for Common Psychotropic Drugs, and Aggression Management in Children and Adolescents Neuroscience-based nomenclature added to Product Availability tables Antipsychotic-Induced Extrapyramidal Side Effect (EPSE) chapter completely revised, plus new section on monitoring scales for EPSE Anxiolytics section on buspirone and benzodiazepine comparison table revised

The aim of this book on psychotherapies with children and families is to present a comprehensive overview of the current array of intervention approaches in the child mental health field. There is a focus on the integration of theory, research, and practice throughout the book. The book proceeds from the more global pre sentations of basic theoretical approaches to applications of these approaches with specific problems and populations. It then presents more integrated intervention approaches and overviews of the research literature. One of the unique features of this book is its focus on future directions for each approach, both in clinical prac tice and in research. A second unique feature is its structured format across di verse approaches with a focus on empirical validation of approaches. Another innovation is the presentation of interventions that integrate major components of different theoretical approaches. Thus, the book reflects the current trends in the field of interventions with specific problems and populations, empirical valida tion of the approach, and the integration of treatment approaches. There are five major sections in this book. Part I consists of four chapters that address a variety of issues related to child psychotherapy. Chapter 1 by the editors examines the historical roots of child psychotherapy and explores current trends in the treatment of diverse child disorders. It emphasizes the movement to "treat ments that work" and sets the stage for the chapters that follow.

This book provides an introduction to the principles of pharmacogenomics and precision medicine, followed by the pharmacogenomics aspects of major therapeutic areas such as cardiovascular disease, cancer, organ transplantation, psychiatry, infection, antithrombotic drugs. It also includes genotyping technology and therapeutic drug monitoring in Pharmacogenomics; ethical, Legal and Regulatory Issues; cost-effectiveness of pharmacogenetics-guided treatment; application of pharmacogenomics in drug discovery and development and clinical Implementation of Pharmacogenomics for Personalized Precision Medicine. The contributors of Pharmacogenomics in Precision Medicine come from a team of experts, including professors from academic institutions and practitioner from hospital. It will give an in-depth overview of the current state of pharmacogenomics in drug therapy for all health care professionals and graduate students in the era of precision medicine.

This work represents the first comprehensive publication in the innovative field of pharmacogenomics, a field which is set to revolutionize pharmaceutical research. In addition to renowned editors, the list of contributors is a "who-is-who" in the field. Broad coverage of all aspects of pharmacogenomics with a full presentation of applications to disease conditions is featured. Anyone involved in pharmaceutical research and drug development needs this book to keep up with this new and revolutionary approach

Pharmacogenomics is the basis of personalized medicine which will be the medicine of the future. Through both reducing the numbers of adverse drug reactions and improving the use of existing drugs in targeted populations, pharmacogenomics represents a real advance on traditional therapeutic drug monitoring. Pharmacogenomics in Clinical Therapeutics provides an introduction to the principles of pharmacogenomics before addressing the pharmacogenomic aspects of key therapeutic areas such as warfarin therapy, cancer chemotherapy, therapy with immunosuppressants, antiretroviral therapy, and psychoactive drugs. It also includes methods of pharmacogenomic testing and the pharmacogenomic aspects of drug–drug interactions. From a team of expert contributors, Pharmacogenomics in Clinical Therapeutics is a comprehensive overview of the current state of pharmacogenomics in pharmacotherapy for all clinicians, pharmacologists and clinical laboratory professionals. It is also a guide for practicing clinicians and health care professionals to the basic principles of pharmacogenomics, laboratory tests currently available to aid clinicians, and the future promise of this developing field.

The terms pharmacogenomics and pharmacogenetics tend to be used interchangeably, and a precise, consensus definition of either remains elusive. Pharmacogenetics is generally regarded as the study of genetic variation that gives rise to differing response to drugs, while pharmacogenomics is the broader application of genomic technologies to new drug discovery and further characterization of older drugs. Pharmacogenetics considers one or at most a few genes of interest, while pharmacogenomics considers the entire genome. Much of current clinical interest is at the level of pharmacogenetics, involving variation in genes involved in drug metabolism with a particular emphasis on improving drug safety. This new book presents leading-edge research in this dynamic field.